Effect of N-acetylcysteine ??and bromhexine pneumothorax

Comparison of the efficacy of N-acetylcysteine and bromhexine in patients with pneumothorax

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220529055014N1

Enrollment

Registered

2022-06-15

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumothorax.

Interventions

Intervention 1: Intervention group: In this group, pneumothorax patients are treated orally for one week by implanting chest tube and taking bromhexine tablets, a product of Aveh Sina Pharmaceutical C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient admitted to the surgical ward Satisfaction with participation in the study Patients with traumatic pneumothorax to a significant extent

Exclusion criteria

Exclusion criteria: Patients with chronic obstrucrive pulmonary disease ( copd ) Asthma cystic fibrosis bronchitis bronchiectasis AIDS Patients who have undergone intubation

Design outcomes

Primary

Measure	Time frame
Normalization of symptoms in chest xray. Timepoint: About a week after starting treatment. Method of measurement: Counting the number of days hospitalized.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Rezaei

Bam University of Medical Sciences

Hossein.rezaei.aliabadi@gmail.com+98 34 4421 9074

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026